Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of solid tumors. PYX-201, the company’s lead clinical drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results